source
- Unicycive Therapeutics receives second FDA complete response letter for kidney drug amid manufacturing problemsUnicycive Therapeutics' chronic kidney disease drug, a phosphate binder called oxylanthanum carbonate (OLC), has been rejected by the U.S. Food and Drug Administration for a second time. The FDA c…
- Beeline Medicines secures $126M from Bain Capital, CPPIB and Bristol Myers to expand immunology pipelineBeeline Medicines, a spinout from Bristol Myers Squibb, announced it has received an additional $126 million in financing. The new capital comes from existing investors Bain Capital and the Canada…